Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.83 |
| ▸ | TEK | Q02763 | 11/20 | 0.83 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | RAF1 | P04049 | 5/20 | 0.56 |
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343542 | 0.91 | KDR (1.00) | KDRTEKCSNK1DRAF1 | |
| Hydrochloric Acid SCHEMBL29710729 | 0.90 | KDR (0.98) | KDRTEKCSNK1DRAF1 | |
| SCHEMBL5351759 | 0.80 | TEK (0.87) | KDRTEKRAF1 | |
| SCHEMBL5342493 | 0.79 | KDR (1.00) | KDRTEKCSNK1DRAF1 | |
| SCHEMBL17287800 | 0.79 | CSNK1D (1.00) | KDRTEKCSNK1DRAF1BRAF | |
| SCHEMBL16317401 | 0.79 | KDR (0.79) | KDRTEKCSNK1DRAF1BRAF | |
| SCHEMBL14375384 | 0.78 | KDR (0.78) | KDRTEKCSNK1DRAF1 | |
| SCHEMBL5349296 | 0.78 | KDR (0.77) | KDRTEKCSNK1DRAF1 | |
| SCHEMBL5341988 | 0.78 | KDR (0.76) | KDRTEKCSNK1DRAF1BRAF | |
| SCHEMBL14375491 | 0.77 | TEK (0.78) | KDRTEKRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | claimed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | claimed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | KDR 2/4885TEK 5/4885CSNK1D 3454/4885 |
| US-20040082583-A1 | Chemical compounds | TIE1, KDR, FLT4 | KDR 2/4885TEK 5/4885CSNK1D 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.